Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
AIMS: To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs).
METHODS AND RESULTS: A genome-wide association study (GWAS) on ACEi discontinuation was conducted, including 33 959 ACEi-discontinuers and 44 041 controls. Cases were defined as persons who switched from an ACEi treatment to an angiotensin receptor blocker. Controls were defined as persons who continued ACEi treatment for at least 1 year. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed for ACEi discontinuation risk by mixed model regression analysis. Summary statistics from the individual cohorts were meta-analyzed with a fixed-effects model. To test for association with specific ACEi-associated ADRs, any genome-wide significant (P < 5 × 10-8) ACEi discontinuation variants was tested for association with ACEi-associated cough and angioedema. A polygenetic risk score (PRS) based on ACEi discontinuation GWAS data was constructed and tested for association with ACEi-associated cough and angioedema in two population-based samples. In total, seven genetic genome-wide loci were identified, of which six were previously unreported. The strongest association with ACEi discontinuation was at 20q13.3 (NTSR1; OR: 1.21; 95% CI: 1.17-1.24; P = 2.1 × 10-34). Five of seven lead variants were associated with ACEi-associated cough, whereas none were associated with ACEi-associated angioedema. The ACEi discontinuation PRS was associated with ACEi-associated cough in a dose-response manner but not with ACEi-associated angioedema. ACEi discontinuation was genetically correlated with important causes for cough, including gastro-esophageal reflux disease, allergic rhinitis, hay fever, and asthma, which indicates partly shared genetic underpinning between these traits.
CONCLUSION: This study showed the advantage of using prescription patterns to discover genetic links with ADRs. In total, seven genetic loci that associated with ACEi discontinuation were identified. There was evidence of a strong association between our ADR phenotype and ACEi-associated cough. Taken together, these findings increase insight into the pathophysiological processes that underlie ACEi-associated ADRs.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
European heart journal - 43(2022), 45 vom: 01. Dez., Seite 4707-4718 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghouse, Jonas [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.12.2022 Date Revised 19.09.2023 published: Print CommentIn: Eur Heart J. 2022 Aug 04;:. - PMID 35924414 Citation Status MEDLINE |
|---|
| doi: |
10.1093/eurheartj/ehac322 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342725289 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342725289 | ||
| 003 | DE-627 | ||
| 005 | 20231226014800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehac322 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342725289 | ||
| 035 | |a (NLM)35751511 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghouse, Jonas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.12.2022 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Eur Heart J. 2022 Aug 04;:. - PMID 35924414 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a AIMS: To search for sequence variants associated with ACEi discontinuation and to test their association with ACEi-associated adverse drug reactions (ADRs) | ||
| 520 | |a METHODS AND RESULTS: A genome-wide association study (GWAS) on ACEi discontinuation was conducted, including 33 959 ACEi-discontinuers and 44 041 controls. Cases were defined as persons who switched from an ACEi treatment to an angiotensin receptor blocker. Controls were defined as persons who continued ACEi treatment for at least 1 year. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were computed for ACEi discontinuation risk by mixed model regression analysis. Summary statistics from the individual cohorts were meta-analyzed with a fixed-effects model. To test for association with specific ACEi-associated ADRs, any genome-wide significant (P < 5 × 10-8) ACEi discontinuation variants was tested for association with ACEi-associated cough and angioedema. A polygenetic risk score (PRS) based on ACEi discontinuation GWAS data was constructed and tested for association with ACEi-associated cough and angioedema in two population-based samples. In total, seven genetic genome-wide loci were identified, of which six were previously unreported. The strongest association with ACEi discontinuation was at 20q13.3 (NTSR1; OR: 1.21; 95% CI: 1.17-1.24; P = 2.1 × 10-34). Five of seven lead variants were associated with ACEi-associated cough, whereas none were associated with ACEi-associated angioedema. The ACEi discontinuation PRS was associated with ACEi-associated cough in a dose-response manner but not with ACEi-associated angioedema. ACEi discontinuation was genetically correlated with important causes for cough, including gastro-esophageal reflux disease, allergic rhinitis, hay fever, and asthma, which indicates partly shared genetic underpinning between these traits | ||
| 520 | |a CONCLUSION: This study showed the advantage of using prescription patterns to discover genetic links with ADRs. In total, seven genetic loci that associated with ACEi discontinuation were identified. There was evidence of a strong association between our ADR phenotype and ACEi-associated cough. Taken together, these findings increase insight into the pathophysiological processes that underlie ACEi-associated ADRs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACE inhibitors | |
| 650 | 4 | |a ACE-inhibitor associated cough | |
| 650 | 4 | |a ADR | |
| 650 | 4 | |a Adverse drug reaction | |
| 650 | 4 | |a Drug discontinuation | |
| 650 | 4 | |a GWAS | |
| 650 | 4 | |a Genome-wide association study | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Tragante, Vinicius |e verfasserin |4 aut | |
| 700 | 1 | |a Muhammad, Ayesha |e verfasserin |4 aut | |
| 700 | 1 | |a Ahlberg, Gustav |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Morten W |e verfasserin |4 aut | |
| 700 | 1 | |a Roden, Dan M |e verfasserin |4 aut | |
| 700 | 1 | |a Jonsdottir, Ingileif |e verfasserin |4 aut | |
| 700 | 1 | |a Andreasen, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Lundegaard, Pia Rengtved |e verfasserin |4 aut | |
| 700 | 1 | |a Trudsø, Linea C |e verfasserin |4 aut | |
| 700 | 1 | |a Banasik, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Brunak, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrowski, Sisse R |e verfasserin |4 aut | |
| 700 | 0 | |a eMERGE consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Torp-Pedersen, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Ole V |e verfasserin |4 aut | |
| 700 | 1 | |a Sørensen, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Køber, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Iversen, Kasper |e verfasserin |4 aut | |
| 700 | 1 | |a Thorsteinsdottir, Unnur |e verfasserin |4 aut | |
| 700 | 1 | |a Thorgeirsson, Gudmundur |e verfasserin |4 aut | |
| 700 | 1 | |a Ullum, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Gudbjartsson, Daniel F |e verfasserin |4 aut | |
| 700 | 1 | |a Mosley, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Hilma |e verfasserin |4 aut | |
| 700 | 1 | |a Stefansson, Kari |e verfasserin |4 aut | |
| 700 | 1 | |a Bundgaard, Henning |e verfasserin |4 aut | |
| 700 | 1 | |a Olesen, Morten Salling |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d 1983 |g 43(2022), 45 vom: 01. Dez., Seite 4707-4718 |w (DE-627)NLM012617253 |x 1522-9645 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:45 |g day:01 |g month:12 |g pages:4707-4718 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/ehac322 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 45 |b 01 |c 12 |h 4707-4718 | ||